Literature DB >> 14965676

MIB-1 assessments in breast cancers.

S Iqbal1, T J Anderson, L P Marson, R J Prescott, J M Dixon, W R Miller.   

Abstract

The variability of MIB-1 measurements in breast cancer was assessed in histological sections from core and excision biopsies taken simultaneously in 13 cases and sequentially (with an intervening period of 2-3 weeks) in 17 cases. Results showed no significant differences in values between cores and sections, whether taken simultaneously or sequentially. Individual pairs of cores and sections occasionally demonstrated substantial differences. The mean ratio of MIB-1 scores between cores and sections was 0.97 [95% confidence interval (CI)=0.68-1.38]. However 95% confidence intervals for ratios within individuals were 0.14-6.68. Although the two samples can be equivalent on an average over numerous patients, they cannot be taken as equivalent within individuals. Severe heterogeneity complicates the assessment of MIB-1 in individual breast cancers and limits utility in monitoring changes in proliferation with treatment.

Entities:  

Year:  2002        PMID: 14965676     DOI: 10.1054/brst.2002.0408

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

1.  Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation.

Authors:  T'ng Chang Kwok; Emad A Rakha; Andrew H S Lee; Matthew Grainge; Andrew R Green; Ian O Ellis; Desmond G Powe
Journal:  Histopathology       Date:  2010-08       Impact factor: 5.087

2.  Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.

Authors:  Gøril Knutsvik; Ingunn M Stefansson; Sura Aziz; Jarle Arnes; Johan Eide; Karin Collett; Lars A Akslen
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

3.  Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.

Authors:  W R Miller; S White; J M Dixon; J Murray; L Renshaw; T J Anderson
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.